Agenus R&D Update to Be Held on November 19, 2015
November 12 2015 - 12:10PM
Business Wire
Agenus Inc. (NASDAQ: AGEN), today announced
additional details for the Company’s upcoming R&D update
session to be held on Thursday, November 19, 2015,
from 4:00 to 7:00 PM Eastern Time at the:
St. Regis Hotel Penthouse Two East 55th Street at Fifth Avenue New
York, NY
The event will provide an overview of Agenus’
recent strategic transactions and progress with its pipeline,
including its checkpoint modulator programs and heat shock
protein-based vaccine Prophage™.
The event will be moderated by Garo Armen, PhD, Chief Executive
Officer and Robert Stein, MD, PhD, Chief Scientific Officer of
Agenus and Head of Research and Development, and will include
presentations by key members of the research management followed by
a discussion.
Agenus presenters
will include:
Prior
Affiliations
-- John Castle, PhD BioNTech, AG., Rosetta, Merck -- Alex
Duncan, PhD Astra Zeneca, Cambridge Antibody Technology -- Dennis
Underwood, PhD Infinity Pharma, Bristol-Myers Squibb, Merck -- Marc
Van Dijk, PhD Genmab, Medarex -- Nicholas Wilson, PhD EMD Serono,
Inc., Novartis, Genentech -- John Goldberg, MD UMMSM, Dana-Farber
Cancer Institute
A live webcast will be accessible from the Company’s website at
www.agenusbio.com/webcast/. A replay of the event will be available
on the company’s website.
About Agenus
Agenus is an immunology company engaged in the discovery and
development of novel checkpoint modulators, vaccines and adjuvants
to treat cancer and other diseases. Using its proprietary platforms
Retrocyte Display™ and SECANT®, the Company is discovering and
developing novel antibodies to target GITR, OX40, CTLA-4, LAG-3,
TIM-3, PD-1, CEACAM1 and other undisclosed checkpoints in partnered
and internal programs. Agenus’ heat shock protein vaccine,
Prophage, has successfully completed Phase 2 studies in newly
diagnosed glioblastoma multiforme. The Company’s QS-21 Stimulon®
adjuvant is partnered with GlaxoSmithKline and Janssen Sciences
Ireland UC. For more information, please visit www.agenusbio.com;
information that may be important to investors will be routinely
posted on our website.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company’s
upcoming R&D update. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of
Agenus’ Form 10-Q filed with the Securities and Exchange Commission
on November 4, 2015. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
press release, and Agenus undertakes no obligation to update or
revise the statements, other than to the extent required by law.
All forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151112006224/en/
Agenus:Agenus Inc.Michelle Linn,
774-696-3803michelle.linn@agenusbio.comorMedia:BMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney, 212-600-1902andrea@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024